| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/05/2006 | US20060003920 LAT1 transporters expressed in cancer cells |
| 01/05/2006 | US20060003916 Parathyroid hormone-related protein (PTHrP) specific antibodies for targeted treatment of kidney, liver and/or lung specic cell proliferative disorders; Antitumor agents |
| 01/05/2006 | US20060003915 Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
| 01/05/2006 | US20060003451 Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus |
| 01/05/2006 | US20060003419 Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| 01/05/2006 | US20060003418 Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| 01/05/2006 | US20060003417 Polypeptide; polyethylene glycolylated polypeptide; antidiabetic agents; side effect reduction |
| 01/05/2006 | US20060003410 Oxidoreductase for use in identifying modulators for prevention and treatment of diabetes, obesity, dyslipidemia, coronary heart, inflammatory and cancer disorders |
| 01/05/2006 | US20060003379 Smad6 and uses thereof |
| 01/05/2006 | US20060003378 Expressed by keratinocytes, wound-healing and chondrosarcoma tissue; nucleic acids comprising polynucleotide of given sequence; use in diagnostics and therapeutics |
| 01/05/2006 | US20060003348 Omi PDZ modulators |
| 01/05/2006 | US20060002991 Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same |
| 01/05/2006 | US20060002969 Methods for reducing the foreign body reaction |
| 01/05/2006 | US20060002963 Use of emulsions for intra and periocular injections |
| 01/05/2006 | US20060002958 Attenuation of metapneumovirus |
| 01/05/2006 | US20060002952 Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
| 01/05/2006 | US20060002934 Egf receptor antagonists in the treatment of gastric cancer |
| 01/05/2006 | US20060002922 Method for preventing or treating obesity by modulating the activities of the pentose phosphate patway |
| 01/05/2006 | US20060002915 Pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis |
| 01/05/2006 | US20060002914 treating or preventing axonal degradation in neuropathic diseases in mammals; axonopathy; administering an agent (such as NAD, NADH) that increases sirtuin activity in diseased and/or injured neurons and supporting cells in an amount effective to decrease axonal degeneration |
| 01/05/2006 | US20060002906 Tolerizing allografts of pluripotent stem cells |
| 01/05/2006 | US20060002905 Mutant forms of EtxB and CtxB and their use as carriers |
| 01/05/2006 | US20060002904 Receptor and related products and methods |
| 01/05/2006 | US20060002897 Plasmid for tissue targeted treatment of tumors; antitumor agents |
| 01/05/2006 | US20060002896 Method of generating recombinant MVA |
| 01/05/2006 | US20060002895 Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery |
| 01/05/2006 | US20060002894 Method for introducing a biological molecule using a viral envelope and composition and system therefor |
| 01/05/2006 | US20060002893 Targeted adenovirus vectors for delivery of heterologous genes |
| 01/05/2006 | US20060002892 Lectin-like transcript (LLTI); Natural killer cells; antitumor agents; quantitative analysis; human lectin transcription factor |
| 01/05/2006 | CA2735272A1 Nerve regeneration by transplanting cells expressing recombinant transforming growth factor superfamily protein |
| 01/05/2006 | CA2589563A1 Method of screening compound directly activating glycogen synthase |
| 01/05/2006 | CA2571852A1 Inhibition of infiltration, and cell killing agent |
| 01/05/2006 | CA2571849A1 Anticancer agent containing dendritic cell having rna virus transferred thereinto |
| 01/05/2006 | CA2571844A1 Anticancer agent containing minus-strand rna virus |
| 01/05/2006 | CA2571611A1 Cell-based therapies for ischemia |
| 01/05/2006 | CA2568150A1 Medical systems and methods for delivering compositions to cells |
| 01/05/2006 | CA2560631A1 Improved inhibitor nucleic acids |
| 01/04/2006 | EP1612281A2 Methods for assessing patients with acute myeloid leukemia |
| 01/04/2006 | EP1612272A2 Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis |
| 01/04/2006 | EP1612269A1 Use of replication-deficient adenoviral vector to boost CD8+ T cell immune response to antigen |
| 01/04/2006 | EP1612219A1 Allergen from house-dust mites |
| 01/04/2006 | EP1611899A1 Combined use of g-csf with angiogenetic factor |
| 01/04/2006 | EP1611248A1 Diagnostic method for glaucoma |
| 01/04/2006 | EP1611237A1 Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby |
| 01/04/2006 | EP1610765A2 Non-aqueous single phase vehicles and formulations utilizing such vehicles |
| 01/04/2006 | EP1610612A2 Endosomolytic polymers |
| 01/04/2006 | EP1311677B1 Regulation of human p2y1-like g protein-coupled receptor |
| 01/04/2006 | EP1307573B1 Adenoviral vectors for the transduction of chondrocytes |
| 01/04/2006 | EP1250422B1 Myeloid colony stimulating factor and uses thereof |
| 01/04/2006 | EP1223950B1 Ribozyme therapy for the treatment of proliferative eye diseases |
| 01/04/2006 | EP1202744B1 PRODUCTION OF rhPBGD |
| 01/04/2006 | EP1146881B1 Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin |
| 01/04/2006 | EP1077728B1 Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy |
| 01/04/2006 | EP1053325B1 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination |
| 01/04/2006 | EP1019518B1 Self-deleting vectors for cancer therapy |
| 01/04/2006 | EP0970243B1 Diagnosis and treatment of glaucoma |
| 01/04/2006 | CN1717488A Recombinant poxvirus comprising at least two cowpox ATI promoters |
| 01/04/2006 | CN1717476A Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
| 01/04/2006 | CN1717254A Methods for treating or preventing angiogenesis-dependent symptoms |
| 01/04/2006 | CN1717250A Anti-cancer and anti-infectious disease compositions and methods for using same |
| 01/04/2006 | CN1717248A Combined tumor treating method by heat shock protein tumor internal administration and cytotoxin agent |
| 01/04/2006 | CN1717177A Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
| 01/04/2006 | CN1714871A Use of human ING4 gene as chemotherapy medicine sensitivity promoter |
| 01/04/2006 | CN1714870A Use of human homology cassette gene LHX4 in preparing medicine for treating phaeochromocytoma |
| 01/04/2006 | CN1714862A Liver cancer relative gene DLK1 and its use |
| 01/04/2006 | CN1234417C Pharmaceutical compositions comprising dendritic cells for immunotherapy of automimmune disease and treatment methods using the same |
| 01/03/2006 | US6982361 Method of screening a compound for anxiolytic activity in an Apolipoprotein e knockout animal |
| 01/03/2006 | US6982320 Cytokine receptor common gamma chain like |
| 01/03/2006 | US6982148 Progressive elevated gene-3 (PEG-3) induces aggressive cancer phenotype and regulates angiogenesis |
| 01/03/2006 | US6982092 Method of complexing a nucleic acid with a lipid-conjugated polyamide |
| 01/03/2006 | US6982087 Attenuating mutations and methods of making them, the alphavirus vector delivers the heterologous nucleotide sequence to the cells of the bone, bone marrow, and/or bone-associated connective tissue |
| 01/03/2006 | US6982082 Gene therapy by cell specific targeting |
| 01/03/2006 | CA2176117C Generation of high titers of recombinant aav vectors |
| 01/03/2006 | CA2158937C Recombinant alphavirus vectors |
| 01/03/2006 | CA2070979C Sequence specific dna binding by p53 |
| 12/29/2005 | WO2005123935A1 Method of producing therapeutically useful product and system |
| 12/29/2005 | WO2005123931A1 System and method for electroporating a sample |
| 12/29/2005 | WO2005123922A1 Porcine sulfotransferase 2a1 polynucleotide sequence, protein, and methods of use for same |
| 12/29/2005 | WO2005123142A1 A method using inorganic nanoparticles as non-viral vectors for gene therapy |
| 12/29/2005 | WO2005123141A2 Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent |
| 12/29/2005 | WO2005123117A1 Treatment of non alcoholic steatotic hepatitis (nash) |
| 12/29/2005 | WO2005094370A3 Oligonucleotide complex compositions and methods of use as gene alteration tools |
| 12/29/2005 | WO2005084387A3 Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer |
| 12/29/2005 | WO2005072364A3 A modified baculovirus expression system for production of pseudotyped raav vector |
| 12/29/2005 | WO2005067500A3 Enhancement of immune responses |
| 12/29/2005 | WO2005065309A3 Lentiviral vector delivery of native and mutated igfbp-3 for treatment of cancer |
| 12/29/2005 | WO2005065121A3 Methods and compositions for the production of monoclonal antibodies |
| 12/29/2005 | WO2005048943A3 Compositions and methods for synergistic induction of antitumor immunity |
| 12/29/2005 | WO2005042552A3 Modulation of sglt2 expression |
| 12/29/2005 | WO2005023996A3 METHODS OF INDUCING THE EXPRESSION OF BONE MORPHOGENETIC PROTEINS (BMPs) AND TRANSFORMING GROWTH FACTOR-β PROTEINS (TGF-βs) IN CELLS |
| 12/29/2005 | WO2005019411A3 Ancestral viruses and vaccines |
| 12/29/2005 | WO2005013918A3 Compositions, methods and kits relating to poxvirus subunit vaccines |
| 12/29/2005 | WO2005004814A3 Sirt1 and genetic disorders |
| 12/29/2005 | WO2005001043A3 METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF FNAi |
| 12/29/2005 | WO2004103269A3 Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia |
| 12/29/2005 | WO2004101745A3 NOVEL REGULATORY MECHANISMS OF NF-kappaB |
| 12/29/2005 | WO2004094599A3 Disease prevention and vaccination following thymic reactivation |
| 12/29/2005 | WO2004067710A3 Compositions and methods for tissue specific targeting of lentivirus vectors |
| 12/29/2005 | WO2004013280A3 ALLELE-SPECIFIC siRNA-MEDIATED GENE SILENCING |
| 12/29/2005 | WO2003072799A3 Brother of the regulator of imprinted sites (boris) |